Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2

Cancer Letters

Volumn 320, Issue 1, 2012, Pages 81-85

  Win Piazza, Hla ^a,d   Schneeberger, Valentina E ^a,b   Chen, Liwei ^a   Pernazza, Daniele ^a   Lawrence, Harshani R ^a   Sebti, Said M ^a,b,c   Lawrence, Nicholas J ^a,c   Wu, Jie ^a,b,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Interferon; Melanoma; Shp2; STAT1

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEGINTERFERON ALPHA2B; PROTEIN KINASE TYK2; PROTEIN TYROSINE PHOSPHATASE SHP 2; RECOMBINANT ALPHA2B INTERFERON; STAT1 PROTEIN; STAT2 PROTEIN; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; INTERFERON-ALPHA; MELANOMA; MICE; MICE, NUDE; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862809540     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.034     Document Type: Article

References (23)

1. Gogas H.J., Kirkwood J.M., Sondak V.K. Chemotherapy for metastatic melanoma: time for a change?. Cancer 2007, 109:455-464.
2. Sabel M.S., Sondak V.K. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist 2003, 8:451-458.
3. McLoughlin J.M., Zager J.S., Sondak V.K., Berk L.B. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control 2008, 15:239-247.
4. Lesinski G.B., Trefry J., Brasdovich M., Kondadasula S.V., Sackey K., Zimmerer J.M., Chaudhury A.R., Yu L., Zhang X., Crespin T.R., Walker M.J., Carson W.E. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin. Cancer Res. 2007, 13:5010-5019.
5. Taniguchi T., Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat. Rev. Mol. Cell Biol. 2001, 2:378-386.
6. Chan G., Kalaitzidis D., Neel B.G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008, 27:179-192.
7. Cunnick J.M., Meng S., Ren Y., Desponts C., Wang H.G., Djeu J.Y., Wu J. Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J. Biol. Chem. 2002, 277:9498-9504.
8. Ren Y., Meng S., Mei L., Zhao Z.J., Jove R., Wu J. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J. Biol. Chem. 2004, 279:8497-8505.
9. Chan R.J., Feng G.-S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007, 109:862-867.
10. Ren Y., Chen Z., Chen L., Woods N.T., Reuther G.W., Cheng J.Q., Wang H.G., Wu J. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. J. Biol. Chem. 2007, 282:36463-36473.
11. Bentires-Alj M., Paez J.G., David F.S., Keilhack H., Halmos B., Naoki K., Maris J.M., Richardson A., Bardelli A., Sugarbaker D.J., Richards W.G., Du J., Girard L., Minna J.D., Loh M.L., Fisher D.E., Velculescu V.E., Vogelstein B., Meyerson M., Sellers W.R., Neel B.G. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004, 64:8816-8820.
12. Ren Y., Chen Z., Chen L., Fang B., Win-Piazza H., Haura E.B., Koomen J.M., Wu J. Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes Cancer 2010, 1:994-1007.
13. Scott L.M., Lawrence H.R., Sebti S.M., Lawrence N.J., Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr. Pharm. Des. 2010, 16:1843-1862.
14. Jiang Z.X., Zhang Z.Y. Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev. 2008, 27:263-272.
15. Wu T.R., Hong Y.K., Wang X.D., Ling M.Y., Dragoi A.M., Chung A.S., Campbell A.G., Han Z.Y., Feng G.S., Chin Y.E. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J. Biol. Chem. 2002, 277:47572-47580.
16. Yi T., Pathak M.K., Lindner D.J., Ketterer M.E., Farver C., Borden E.C. Anticancer activity of sodium stibogluconate in synergy with IFNs. J. Immunol. 2002, 169:5978-5985.
17. Pathak M.K., Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 2001, 167:3391-3397.
18. Singh S., Davis R., Alamanda V., Pireddu R., Pernazza D., Sebti S., Lawrence N., Chellappan S. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine. Mol. Cancer Ther. 2010, 9:3330-3341.
19. Chen L., Pernazza D., Scott L.M., Lawrence H.R., Ren Y., Luo Y., Wu X., Sung S.S., Guida W.C., Sebti S.M., Lawrence N.J., Wu J. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochem. Pharmacol. 2010, 80:801-810.
20. Ren Y., Chen Z., Chen L., Fang B., Win-Piazza H., Haura E., Koomen J.M., Wu J. Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes Cancer 2010, 1:994-1007.
21. Sun T., Zhao N., Ni C.S., Zhao X.L., Zhang W.Z., Su X., Zhang D.F., Gu Q., Sun B.C. Doxycycline inhibits the adhesion and migration of melanoma cells by inhibiting the expression and phosphorylation of focal adhesion kinase (FAK). Cancer Lett. 2009, 285:141-150.
22. Lawrence H.R., Pireddu R., Chen L., Luo Y., Sung S.S., Szymanski A.M., Yip M.L., Guida W.C., Sebti S.M., Wu J., Lawrence N.J. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J. Med. Chem. 2008, 51:4948-4956.
23. Hellmuth K., Grosskopf S., Lum C.T., Wurtele M., Roder N., von Kries J.P., Rosario M., Rademann J., Birchmeier W. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc. Natl Acad. Sci. USA 2008, 105:7275-7280.